Resistance to Cotrimoxazole and Other Antimicrobials among Isolates from HIV/AIDS and Non-HIV/AIDS Patients at Bugando Medical Centre, Mwanza, Tanzania

Table 2

Susceptibility data for common bacterial isolates to cotrimoxazole and other antimicrobials regardless of HIV or cotrimoxazole prophylaxis status.

	Resistant	Susceptible		Resistant	Susceptible
	%	%		%	%
	Cotrimoxazole			Amoxycillin-clavulanic
Bacteria isolates
E. coli	54 (84.4)	10 (15.6)	0.1	27 (43.6)	35 (56.4)	<0.001
S. aureus	14 (56.0)	11 (44.0)		3 (13.0)	20 (87.0)
K. pneumoniae	20 (74.1)	7 (25.9)		20 (83.3)	4 (16.7)
P. aeruginosa	7 (87.5)	1 (12.5)		6 (75.0)	2 (25.0)
Proteus	17 (80.9)	4 (19.1)		10 (47.6)	11 (52.4)
	Erythromycin			Ceftriaxone
Bacteria isolates
E. coli	2 (50.0)	2 (50.0)		16 (48.5)	17 (51.5)	0.08
S. aureus	8 (57.1)	6 (42.9)		4 (30.8)	9 (69.2)
K. pneumoniae	3 (60.0)	2 (40.0)		13 (72.2)	5 (27.9)
P. aeruginosa	0 (0.0)	2 (100.0)		1 (25.0)	3 (75.0)
Proteus	—	—		4 (33.3)	8 (66.7)
	Ciprofloxacin			Ampicillin
Bacteria isolates
E. coli	20 (32.8)	41 (67.2)	0.49	47 (82.5)	10 (17.5)	0.001
S. aureus	3 (13.6)	19 (86.4)		3 (30.0)	7 (70.0)
K. pneumoniae	6 (26.1)	17 (73.9)		21 (95.4)	1 (4.6)
P. aeruginosa	1 (16.7)	5 (83.3)		6 (75.0)	2 (25.0)
Proteus	5 (25.0)	15 (75.0)		16 (76.2)	5 (23.8)
	Tetracycline			Cefuroxime
Bacteria isolates
E. coli	29 (78.4)	8 (21.6)	0.03	11 (64.7)	6 (35.3)	0.60
S. aureus	4 (44.4)	5 (55.6)		3 (37.5)	5 (62.5)
K. pneumoniae	19 (95.0)	1 (5.0)		10 (71.4)	4 (28.6)
P. aeruginosa	5 (100.0)	0 (0.0)		2 (66.7)	1 (33.3)
Proteus	14 (82.4)	3 (17.6)		5 (45.5)	6 (54.5)